


Sickle cell target could treat COVID

January 28 2021, by Hayley Jarvis



Normal blood cells next to a sickle-blood cell, colored scanning electron microscope image. Credit: Wikipedia/Illustration from Anatomy & Physiology

Scientists have found a way to lower stroke risk in sickle cell patients that opens a gateway of potential treatments for inflammation and clotting stemming from conditions such as COVID-19. For the first time, they investigated the use of immune cell proteins as an anti-inflammatory treatment to reduce blood clotting in people with sickle cell disease.

A study published today in the journal *Blood* explains how the peptide Ac2-26 flips a biological switch in [immune cells](#) in people with [sickle cell disease](#).

"We are particularly excited," said Professor Felicity Gavins, director of the Centre for Inflammation Research and Translational Medicine (CIRTM) at Brunel University London. "We have targeted a pathophysiological immune response to help the body fight disease. It paves the way for new therapies to prevent disorders associated with thrombo-inflammation, which is linked to a raft of conditions which may include COVID-19."

COVID-19, like sickle cell disease, triggers dangerous inflammation and thrombosis (blood clotting), which can lead to the increased risk of strokes, heart attacks and pulmonary embolism ([blood clotting](#) in the lungs). The result could also make a big difference for older people because the risk of thrombosis and inflammation rises with age.

The team studied blood from 91 people aged between 18 and 52, half

with sickle cell disease. The peptide Ac2-26 is found in immune cells or [white blood cells](#) called neutrophils. When triggered, Ac2-26 switches on a pathway—a protein and receptor that quickly calm inflammation.

Neutrophils act like [first responders](#) and are first on the scene in an emergency. There, as in fishing, they cast out NETs (neutrophil extracellular traps) to catch pathogens and protect the body. But sometimes, NETs can also fuel disease. They stack up and form a scaffold that other cells such as platelets stick to. This build-up causes thrombo-inflammation—a hallmark of many diseases and conditions including sickle cell disease, chronic kidney disease, sepsis and cancer.

This is the first study to show that the peptide Ac2-26 can be used to change how neutrophils respond in people with sickle cell disease so that they lose the ability to produce harmful NETs that can cause thrombo-inflammation. "These unique findings may spur drug discovery for not only sickle cell disease, but also other diseases connected to thrombo-inflammation, such as ischaemic stroke, aging, heart disease, cancer and even COVID-19," said Professor Gavins.

More information: Junaid Ansari et al. Targeting AnxA1/Fpr2/ALX Pathway Regulates Neutrophil Function Promoting Thrombo-Inflammation Resolution in Sickle Cell Disease, *Blood* (2021). [DOI: 10.1182/blood.2020009166](#)

Provided by Brunel University

Citation: Sickle cell target could treat COVID (2021, January 28) retrieved 8 May 2024 from <https://medicalxpress.com/news/2021-01-sickle-cell-covid.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private

study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.